

NIHR

Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews

Uncertainty remains over the optimal prediction model(s) for use in clinical practice to assess prognosis. In general, there was insufficient evidence that the effect of treatment depended on baseline characteristics and thus they couldn't be used as predictive markers of treatment response.

Health Technology Assessment

Systematic search: Yes

December 2018

<https://www.journalslibrary.nihr.ac.uk/hta/hta22660/#/abstract>

Low-dose computed tomography (LDCT) for lung cancer screening in high-risk populations: a systematic review and economic evaluation

LDCT screening may be clinically effective in reducing lung cancer mortality, but there is considerable uncertainty. There is evidence that a single round of screening could be considered cost-effective at conventional thresholds, but there is significant uncertainty about the effect on costs and the magnitude of benefits

Health Technology Assessment

Systematic search: Yes

December 2018

<https://www.journalslibrary.nihr.ac.uk/hta/hta22690/#/abstract>

Contrast-enhanced ultrasound and/or colour duplex ultrasound for surveillance after endovascular abdominal aortic aneurysm repair: a systematic review and economic evaluation

Current surveillance practice is very heterogeneous. Colour duplex ultrasound (CDU) may be a safe and cost-effective alternative to Computed tomography angiography (CTA), with CTA being reserved for abnormal/inconclusive CDU cases.

Health Technology Assessment

Systematic search: Yes

December 2018

<https://www.journalslibrary.nihr.ac.uk/hta/hta22720/#/abstract>

KINGS FUND

Nil

Scottish Medicines Consortium

brivaracetam

Brivaracetam (Briviact) is accepted for restricted use within NHS Scotland as an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 4 years to ≤ 15 years of age with epilepsy.

Brivaracetam is restricted to use in patients with refractory epilepsy and treatment

should be initiated by physicians who have appropriate experience in the treatment of epilepsy.

SMC advice

Systematic search: No

December 2018

<https://www.scottishmedicines.org.uk/medicines-advice/brivaracetam-briviact-abbreviated-smc2113/>

pertuzumab

Pertuzumab (Perjeta) is accepted for use within NHS Scotland in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2 positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.

SMC advice

Systematic search: No

December 2018

<https://www.scottishmedicines.org.uk/medicines-advice/pertuzumab-perjeta-resubmission-smc2119/>

pembrolizumab

Pembrolizumab (Keytruda) is not recommended for use within NHS Scotland as monotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a $\geq 50\%$ TPS and progressing on or after platinum-containing chemotherapy.

SMC advice

Systematic search: No

December 2018

<https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-nonsub-smc2143/>

ocrelizumab

Ocrelizumab (Ocrevus) is accepted for restricted use within NHS Scotland for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Ocrelizumab is restricted to the treatment of relapsing remitting multiple sclerosis (RRMS) in adults with active disease defined by clinical or imaging features who are contra-indicated or otherwise unsuitable for alemtuzumab.

SMC advice

Systematic search: No

December 2018

<https://www.scottishmedicines.org.uk/medicines-advice/ocrelizumab-ocrevus-resubmission-smc2121/>

ciclosporin

Ciclosporin 1mg/mL (0.1%) eye drops emulsion (Verkazia) is accepted for use within NHS Scotland for the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age, and adolescents.

SMC advice

Systematic search: No

December 2018

<https://www.scottishmedicines.org.uk/medicines-advice/ciclosporin-verkazia-fullsubmission-smc2111/>

nivolumab

nivolumab (Opdivo) is accepted for use within NHS Scotland as monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

SMC advice

Systematic search: No

December 2018

<https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-full-submission-smc2112/>

SGHD

Nil

SIGN

Nil

HEALTH SCOTLAND

Nil

NICE

CG62 Antenatal care for uncomplicated pregnancies

This guideline covers the care that healthy women and their babies should be offered during pregnancy. It aims to ensure that pregnant women are offered regular check-ups, information and support. In December 2018, we withdrew recommendations on alcohol consumption in pregnancy and added a link to the UK CMOs' low-risk drinking guidelines.

NICE Guideline

Systematic search: Yes

December 2018

<https://www.nice.org.uk/guidance/cg62>

NG114 Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing

This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.

NICE Guideline

Systematic search: Yes

December 2018

<https://www.nice.org.uk/guidance/ng114>

NG115 Chronic obstructive pulmonary disease in over 16s: diagnosis and management

This guideline covers diagnosing and managing chronic obstructive pulmonary disease in people aged 16 and older, which includes emphysema and chronic bronchitis. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.

NICE Guideline

Systematic search: Yes

December 2018

<https://www.nice.org.uk/guidance/ng115>

NG116 Post-traumatic stress disorder

This guideline covers recognising, assessing and treating post-traumatic stress disorder in children, young people and adults. It aims to improve quality of life by reducing symptoms of PTSD such as anxiety, sleep problems and difficulties with concentration. Recommendations also aim to raise awareness of the condition and improve coordination of care.

NICE Guideline

Systematic search: Yes

December 2018

<https://www.nice.org.uk/guidance/ng116>

NG117 Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing

This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.

NICE Guideline

Systematic search: Yes

December 2018

<https://www.nice.org.uk/guidance/ng117>

TA550 Vandetanib for treating medullary thyroid cancer

Vandetanib is not recommended for treating aggressive and symptomatic medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease.

NICE Technology Appraisal

Systematic search: Yes

December 2018

<https://www.nice.org.uk/guidance/ta550>

TA551 Lenvatinib for untreated advanced hepatocellular carcinoma

Lenvatinib is recommended as an option for untreated, advanced, unresectable hepatocellular carcinoma in adults, only if they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

NICE Technology Appraisal

Systematic search: Yes

December 2018

<https://www.nice.org.uk/guidance/ta551>

TA552 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia

Liposomal cytarabine–daunorubicin is recommended as an option for untreated therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes in adults.

NICE Technology Appraisal

Systematic search: Yes

December 2018

<https://www.nice.org.uk/guidance/ta552>

TA553 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence

Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of stage III melanoma with lymph node involvement in adults who have had complete resection.

NICE Technology Appraisal

Systematic search: Yes

December 2018

<https://www.nice.org.uk/guidance/ta553>

TA554 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

Tisagenlecleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

NICE Technology Appraisal

Systematic search: Yes

December 2018

<https://www.nice.org.uk/guidance/ta554>

EPPI Centre

Nil

AHRQ (Agency for Healthcare Research and Quality - USA)

Nil

Health Foundation

Nil

Canadian Agency for Drugs and Technologies in Health (CADTH)

Deep Brain Stimulation for Parkinson's Disease: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

The clinical evidence on the effectiveness of deep brain stimulation for Parkinson's disease compared to standard of care (i.e., best medical therapy) was mixed. Some evidence suggests deep brain stimulation may be clinically effective at managing Parkinson's disease symptoms compared to standard of care. Economic evaluations suggest deep brain stimulation may be a cost-effective treatment option compared to standard of care. One evidence-based guideline recommends deep brain stimulation for people with advanced Parkinson's disease whose symptoms are not adequately controlled by best medical therapy.

CADTH Rapid Response Report

Systematic search: Limited

December 2018

<https://www.cadth.ca/deep-brain-stimulation-parkinsons-disease-review-clinical-effectiveness-cost-effectiveness-and>

Nociception Monitoring for General Anesthesia: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Limited evidence suggests that in adult patients undergoing surgery under general anesthesia, the intraoperative opioid consumption is generally less with nociception monitoring compared with standard monitoring, however the between group differences were not always statistically significant.

CADTH Rapid Response Report

Systematic search: Limited

December 2018

<https://www.cadth.ca/nociception-monitoring-general-anesthesia-review-clinical-effectiveness-cost-effectiveness-and-0>

McGill University Health Centre (Canada)

Nil

Health Information & Quality Authority (Ireland)

HTA of extending the HPV vaccination to boys

A change to the HPV immunisation programme should include adoption of the 9-valent vaccine. A gender-neutral 9-valent programme was estimated to be more effective and more costly than the girls-only 9-valent alternative. In light of the conservative assumptions regarding price, uptake rate and exclusion of protection versus oropharyngeal cancer in the base case as well as the proposed decrease in the discount rate from 5% to 4%, it is likely that gender neutral 9-valent vaccination would be considered cost-effective at €45,000 per quality-adjusted life year (QALY).

Health Technology Assessment

Systematic search: Yes

December 2018

<https://www.hiqa.ie/reports-and-publications/health-technology-assessment/hta-extending-hpv-vaccination-boys>

Campbell Collaboration

Nil

Glasgow Centre for Population Health

Nil

NICE FORWARD PLANNING – Publications due January 2019

Renal and ureteric stones: assessment and management
Clinical Guideline

Regorafenib for previously treated advanced hepatocellular carcinoma
Single Technology Appraisal

Darvadstrocel for treating complex perianal fistula in Crohn's disease
Single Technology Appraisal

Short bowel syndrome - teduglutide
Single Technology Appraisal

Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer
Single Technology Appraisal

Cerebral palsy in adults
Clinical Guideline

Nivolumab for adjuvant treatment of resected stage III and IV melanoma
Single Technology Appraisal

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies
Single Technology Appraisal

Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma
Single Technology Appraisal